3Q Revenues: $49 million (+4%)
3Q Loss: $2.0 million (earnings were $87.5 million in 3Q07)
Comments: Total product sales were $28.9 million in the quarter (+16%) driven by Oncaspar sales, up 19% to $12.5 million. Contract manufacturing revenues were $5.3 million (+40%) due to growth from additional business and timing of shipments to customers. Royalty revenues were $14.6 million (-20%) as a result of the sold portion of Peg-Intron royalties. R&D expenses increased to $15.7 million (+49%) primarily due to $1.0 million in milestones related to the LNA platform program and the increase in costs associated with manufacturing process improvements and pharmaceutical properties of Oncaspar and Adagen.